Boston Family Office LLC Sells 5,278 Shares of Merck & Co., Inc. (MRK)

Boston Family Office LLC lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 4.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 102,041 shares of the company’s stock after selling 5,278 shares during the period. Boston Family Office LLC’s holdings in Merck & Co., Inc. were worth $7,797,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. King Luther Capital Management Corp raised its stake in shares of Merck & Co., Inc. by 1.3% during the 4th quarter. King Luther Capital Management Corp now owns 1,719,835 shares of the company’s stock valued at $131,413,000 after purchasing an additional 22,395 shares during the period. NumerixS Investment Technologies Inc bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $1,176,000. Highland Private Wealth Management raised its stake in shares of Merck & Co., Inc. by 2.5% during the 4th quarter. Highland Private Wealth Management now owns 9,314 shares of the company’s stock valued at $711,000 after purchasing an additional 225 shares during the period. Banco Santander S.A. raised its stake in shares of Merck & Co., Inc. by 3.2% during the 4th quarter. Banco Santander S.A. now owns 340,046 shares of the company’s stock valued at $25,982,000 after purchasing an additional 10,666 shares during the period. Finally, Employees Retirement System of Texas raised its stake in shares of Merck & Co., Inc. by 23.2% during the 4th quarter. Employees Retirement System of Texas now owns 509,119 shares of the company’s stock valued at $38,902,000 after purchasing an additional 95,900 shares during the period. 73.60% of the stock is currently owned by hedge funds and other institutional investors.

MRK has been the topic of a number of analyst reports. BMO Capital Markets lowered Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective on the stock. in a research note on Wednesday, January 23rd. Zacks Investment Research lowered Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 24th. Argus boosted their price objective on Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 20th. Cantor Fitzgerald initiated coverage on Merck & Co., Inc. in a research note on Friday, February 22nd. They set an “overweight” rating and a $95.00 price objective on the stock. Finally, ValuEngine lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Merck & Co., Inc. presently has an average rating of “Buy” and an average target price of $82.92.

Shares of NYSE MRK opened at $77.42 on Wednesday. The stock has a market capitalization of $211.19 billion, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 1.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.37. Merck & Co., Inc. has a twelve month low of $57.49 and a twelve month high of $83.85.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, April 30th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.17. The business had revenue of $10.82 billion for the quarter, compared to analyst estimates of $10.45 billion. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.05 EPS. Research analysts forecast that Merck & Co., Inc. will post 4.72 EPS for the current fiscal year.

In other Merck & Co., Inc. news, VP Rita A. Karachun sold 64,662 shares of the company’s stock in a transaction dated Thursday, February 14th. The stock was sold at an average price of $78.96, for a total value of $5,105,711.52. Following the transaction, the vice president now directly owns 53,327 shares in the company, valued at approximately $4,210,699.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Merck & Co., Inc. bought 4,121,683 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $65,946,928.00. The disclosure for this purchase can be found here. Insiders sold a total of 831,287 shares of company stock worth $67,317,987 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Boston Family Office LLC Sells 5,278 Shares of Merck & Co., Inc. (MRK)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/15/boston-family-office-llc-sells-5278-shares-of-merck-co-inc-mrk.html.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: Backdoor Roth IRA

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.